2Seventy Bio Inc
NASDAQ:TSVT
2Seventy Bio Inc
NASDAQ:TSVT
Price:
4.95
USD
-0.2%
Market Cap:
255.4m
USD
Income Statement
Earnings Waterfall
2Seventy Bio Inc
2Seventy Bio Inc
|
Revenue
|
45.6m
USD
|
|
Cost of Revenue
|
-15.6m
USD
|
|
Gross Profit
|
30m
USD
|
|
Operating Expenses
|
-168.7m
USD
|
|
Operating Income
|
-138.7m
USD
|
|
Other Expenses
|
44.2m
USD
|
|
Net Income
|
-94.5m
USD
|
Income Statement
2Seventy Bio Inc
2Seventy Bio Inc
Currency: USD
Millions
TTM
| Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Revenue |
57
N/A
|
51
-10%
|
92
+78%
|
125
+36%
|
147
+18%
|
146
-1%
|
100
-31%
|
71
-29%
|
44
-38%
|
46
+3%
|
|
| Gross Profit | |||||||||||
| Cost of Revenue |
(5)
|
(13)
|
(17)
|
(31)
|
(31)
|
(29)
|
(17)
|
(16)
|
(15)
|
(16)
|
|
| Gross Profit |
52
N/A
|
39
-25%
|
75
+93%
|
94
+25%
|
116
+24%
|
117
+1%
|
83
-29%
|
55
-34%
|
29
-47%
|
30
+2%
|
|
| Operating Income | |||||||||||
| Operating Expenses |
(343)
|
(334)
|
(328)
|
(313)
|
(311)
|
(301)
|
(300)
|
(266)
|
(212)
|
(169)
|
|
| Selling, General & Administrative |
(89)
|
(85)
|
(80)
|
(76)
|
(79)
|
(72)
|
(69)
|
(61)
|
(52)
|
(52)
|
|
| Research & Development |
(254)
|
(248)
|
(249)
|
(237)
|
(232)
|
(229)
|
(231)
|
(206)
|
(162)
|
(119)
|
|
| Other Operating Expenses |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
2
|
2
|
2
|
|
| Operating Income |
(292)
N/A
|
(295)
-1%
|
(254)
+14%
|
(220)
+13%
|
(195)
+11%
|
(184)
+6%
|
(217)
-18%
|
(211)
+3%
|
(183)
+13%
|
(139)
+24%
|
|
| Pre-Tax Income | |||||||||||
| Interest Income Expense |
0
|
2
|
3
|
5
|
8
|
10
|
12
|
13
|
13
|
12
|
|
| Non-Reccuring Items |
(10)
|
(10)
|
(10)
|
(4)
|
0
|
(21)
|
(21)
|
(26)
|
(34)
|
(13)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(5)
|
43
|
43
|
|
| Total Other Income |
17
|
11
|
6
|
4
|
7
|
11
|
8
|
6
|
4
|
3
|
|
| Pre-Tax Income |
(284)
N/A
|
(292)
-3%
|
(254)
+13%
|
(215)
+15%
|
(180)
+16%
|
(184)
-2%
|
(218)
-18%
|
(223)
-3%
|
(156)
+30%
|
(95)
+39%
|
|
| Net Income | |||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(284)
|
(292)
|
(254)
|
(215)
|
(180)
|
(184)
|
(218)
|
(223)
|
(156)
|
(95)
|
|
| Net Income (Common) |
(284)
N/A
|
(292)
-3%
|
(254)
+13%
|
(215)
+15%
|
(180)
+16%
|
(184)
-2%
|
(218)
-18%
|
(223)
-3%
|
(156)
+30%
|
(95)
+39%
|
|
| EPS (Diluted) |
-7.4
N/A
|
-7.47
-1%
|
-7.13
+5%
|
-4.95
+31%
|
-3.53
+29%
|
-3.59
-2%
|
-4.42
-23%
|
-4.28
+3%
|
-2.84
+34%
|
-1.8
+37%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
